Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Cerny, B. Borisch, M. Introna, Peter Johnson, Andrea Rose (2002)
Mechanism of action of rituximabAnti-Cancer Drugs, 13
Cornelis Sier, K. Gelderman, F. Prins, A. Gorter (2004)
Beta‐glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activationInternational Journal of Cancer, 109
C. Reilly, Jack Taylor, D. Lanza, B. Carr, D. Crouch, G. Yost (2003)
Capsaicinoids cause inflammation and epithelial cell death through activation of vanilloid receptors.Toxicological sciences : an official journal of the Society of Toxicology, 73 1
Z. Madjd, L. Durrant, S. Pinder, I. Ellis, J. Ronan, S. Lewis, N. Rushmere, I. Spendlove (2005)
Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?Cancer Immunology, Immunotherapy, 54
K. Gelderman, V. Blok, G. Fleuren, A. Gorter (2002)
The Inhibitory Effect of CD46, CD55, and CD59 on Complement Activation After Immunotherapeutic Treatment of Cervical Carcinoma Cells with Monoclonal Antibodies or Bispecific Monoclonal AntibodiesLaboratory Investigation, 82
S. Jacobs, K. Foon (2005)
Monoclonal antibody therapy of leukaemias and lymphomasExpert Opinion on Biological Therapy, 5
L. Yuste, J. Montero, A. Esparís-Ogando, A. Pandiella (2005)
Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.Cancer research, 65 15
H. Langeggen, M. Pausa, E. Johnson, C. Casarsa, Francesco Tedesco (2000)
The endothelium is an extrahepatic site of synthesis of the seventh component of the complement systemClinical & Experimental Immunology, 121
Non - small cell
C. Spiridon, Sarah Guinn, E. Vitetta (2004)
A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 AntibodiesClinical Cancer Research, 10
Line Bjørge, H. Stoiber, M. Dierich, Seppo Meri (2006)
Minimal Residual Disease in Ovarian Cancer as a Target for Complement‐Mediated mAb ImmunotherapyScandinavian Journal of Immunology, 63
P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, Francesco Tedesco (2007)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.Cancer research, 67 21
(1996)
Phase II study of weekly intravenous humanized antip 185 HER 2 monoclonal antibody in patients with HER 2 / neu overexpressing metastatic breast cancer
Bo Guo, Zheng Ma, Hua Li, Gui-lian Xu, P. Zheng, Bo Zhu, Yu-Zhang Wu, Q. Zou (2008)
Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.Clinical immunology, 128 2
(2002)
clinical trials with trastuzumab : their foundation and preliminary results
S. Treon, C. Mitsiades, N. Mitsiades, G. Young, D. Doss, R. Schlossman, K. Anderson (2001)
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell MalignanciesJournal of Immunotherapy, 24
F. Hirsch, W. Franklin, R. Veve, M. Varella-Garcia, P. Bunn (2002)
HER2/neu expression in malignant lung tumors.Seminars in oncology, 29 1 Suppl 4
P. Bunn, B. Helfrich, Ariel Soriano, Wilbur Franklin, Marileila Varella-Garcia, Fred Hirsch, Anna Barón, C. Zeng, Daniel Chan (2001)
Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 10
J. Kern, L. Torney, D. Weiner, A. Gazdar, H. Shepard, B. Fendly (1993)
Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.American journal of respiratory cell and molecular biology, 9 4
K. Shimo, M. Mizuno, J. Nasu, S. Hiraoka, C. Makidono, H. Okazaki, Kazuhide Yamamoto, H. Okada, T. Fujita, Y. Shiratori (2004)
Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinomaJournal of Gastroenterology and Hepatology, 19
K. Gelderman, P. Kuppen, N. Okada, G. Fleuren, A. Gorter (2004)
Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Crry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases ModelCancer Research, 64
K. Kawano, S. Ferrone, C. Ioannides (2005)
Functional idiotopes: tumor antigen-directed expression of CD8+ T-cell epitopes nested in unique NH2-terminal VH sequence of antiidiotypic antibodies?Cancer research, 65 14
Federica Ziller, P. Macor, R. Bulla, D. Sblattero, R. Marzari, Francesco Tedesco (2005)
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement‐regulatory proteins CD55 and CD59European Journal of Immunology, 35
C. Swanton, A. Futreal, T. Eisen (2006)
Her2-Targeted Therapies in Non–Small Cell Lung CancerClinical Cancer Research, 12
R. Nahta, F. Esteva (2006)
Herceptin: mechanisms of action and resistance.Cancer letters, 232 2
(1990)
Synthesis of C 3 , C 5 , C 6 , C 7 , C 8 , and C 9 by human fibroblasts
Francesco Tedesco, R. Bulla, F. Fischetti (2004)
Terminal Complement Complex: Regulation of Formation and Pathophysiological Functions
(2004)
: report of a phase II trial and findings regarding optimal identification of patients with Her 2 - overexpressing disease
Human monoclonal anti-Her2/neu antibody (herceptin, also named trastuzumab) failed in the treatment of lung cancer when in combination with two chemotherapy agents gemcitabine and cisplatin, despite of its clinical benefit in women with Her2 positive breast cancer. The capacity of herceptin to activate human complement and complement-dependent cytotoxicity against tumor cells was investigated in a study of tumor immunotherapy. We found that the expression of membrane complement regulatory proteins (mCRPs), CD55 and CD59 on non-small cell lung cancer (NSCLC) cells was closely correlated with histological types, prognosis and preoperational adjutant chemotherapy of the disease. Herceptin-mediated complement cytotoxicity to two human lung carcinoma cell lines exerted stronger killing effect on tumor cells after the neutralization of mCPRs via their antibodies. Furthermore, treatment of herceptin combined with chemo-agents had advantages over chemotherapy alone, while CD55 and CD59 expression levels both declined remarkably in A549 and H157 cell lines after incubation with IC50 cisplatin for 72 h. Our data indicated that overexpression of mCRPs on tumor cells contributes to herceptin's acquisition of resistance to NSCLC, and its anticancer efficacy was enhanced when mCRPs were neutralized or cisplatin could be used to down-regulate their expression.
Oncology Reports – Spandidos Publications
Published: Jun 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.